Therefore, the results obtained in this study utilizing IGF-1R antagonists provide a rationale for further pre-clinical studies in order to dissect the IGF-1R signaling pathway to obtain full benefit from this receptor targeted therapy as a single agent or in combination against CRC as well as other solid tumors dependent upon IGF-1R signaling. This evidence concerns the gene IGF1R and colorectal carcinoma.